N,N-Dimethylacetamide veterinary grade is controlled as a Class 2 residual solvent in veterinary pharmaceutical manufacturing; the permitted daily exposure under VICH GL18(R2) and ICH Q3C is 10.9 mg/day, equivalent to 1,090 ppm under the 10 g daily intake convention. Each application area is limited to actual production routes in which DMA functions as a solvent, cosolvent, or transient processing aid rather than as an active substance, and the addition ratios shown are formulation-stage inputs that must be re-verified against finished-product residual-solvent data.

What governs the choice of DMA in sterile injectable vehicles for lipophilic veterinary actives?

Sterile injectable lines for cattle, swine, and companion animal antiparasitic or antimicrobial actives consistently encounter solubility constraints when a molecule exhibits an OECD 117 HPLC log P above 3.5 and shake-flask water solubility below 0.1 mg/mL. DMA functions here as a water-miscible aprotic vehicle, not as a stabilising excipient; its solvation of a lipophilic API proceeds through polar aprotic interaction with the amide carbonyl, allowing single-phase aqueous–organic vehicles to pass through 0.22 µm sterilizing-grade polyethersulfone or polyvinylidene fluoride filters without phase inversion. Compliance for this dosage segment is anchored to VICH GL18(R2), which retains DMA in Class 2 with a permitted daily exposure of 10.9 mg/day, and to USP <467> for headspace gas chromatographic confirmation after batch release; sterility assurance follows EU GMP Annex 1 for aseptic processing if the drug substance is thermolabile, with filter integrity testing executed at 1.0 bar minimum bubble point on each batch. In formulations where terminal autoclaving at 121°C for 15 min is feasible, the DMA content in the final vehicle is typically maintained at 15–35% v/v to avoid excessive dimethylamine generation from hydrolysis; above 35% v/v the pH shift after sterilization can exceed 0.5 pH units and must be controlled with citrate or acetate buffers. The production sequence for a 500 L batch begins with nitrogen-blanketed charging of DMA into a 316L stainless steel jacketed vessel at 25–40°C, followed by API dissolution under low-shear agitation at 150–250 rpm, then addition of purified water and co-solvent at a controlled rate to prevent thermal shock; the solution is polish-filtered through 0.45 µm hydrophobic PVDF and subsequently sterilizing-filtered before filling into 50 mL, 100 mL, and 250 mL Type II glass or high-density polyethylene vials. Finished product types include ready-to-use subcutaneous and intramuscular injectable solutions for endoparasite and ectoparasite control, along with injectable antibiotics for bovine respiratory disease where rapid systemic absorption from a non-aqueous vehicle is required. Operational boundaries are specific: DMA must not be combined with sodium nitrite or nitrite-based preservatives because secondary amine hydrolysis can generate N-nitrosodimethylamine; closure systems must use fluoropolymer-coated butyl stoppers because uncoated elastomer can absorb DMA and alter stopper dimensions during storage; and terminal sterilization of unbuffered DMA-water systems above 30% v/v is not recommended without forced degradation verification.

In veterinary tablet and capsule manufacturing, moisture-sensitive actives that undergo hydrolysis at free-water activities above 0.4 cannot be granulated with aqueous binders without affecting assay and related-substance profiles. DMA is introduced as a non-aqueous granulation solvent at a charge rate of 4–8% w/w based on dry powder blend mass, sprayed through a top-spray binary nozzle in a fluidized-bed granulator equipped with an air inlet dew point below -10°C and inlet air temperature of 45–65°C. The solvent dissolves a portion of the polymeric binder, typically povidone or copovidone, forming in situ granulation bridges; mean droplet size is maintained at 20–40 µm to improve wetting of hydrophobic actives without over-wet massing. Regulatory control for this route is defined by ICH Q3C and VICH GL18(R2), with DMA classified as Class 2 and a per-day limit of 10.9 mg/day; for a 500 mg tablet mass dosed once daily, the calculated Option 1 residual ceiling is 21,800 ppm, while for a 10 g oral bolus dosed once daily the ceiling is 1,090 ppm. Drying is the critical process boundary: after granulation, vacuum drying in a double-cone rotary vacuum dryer at 60 ± 5°C and 5–10 kPa for 8–16 h reduces residual DMA below 0.05% w/w in most formulations, but overdrying above 70°C can cause partial amorphization and subsequent tablet capping. The granules are milled through a 0.8 mm conical screen, blended with extragranular disintegrant, and compressed on a rotary tablet press at 10–20 kN main compression force; capsules are filled using a dosator or tamping-pin capsule filler with 0–2% sodium stearyl fumarate as lubricant. Finished products include immediate-release tablets, hard gelatin capsules, and granules for oral administration in companion animals and horses. DMA is incompatible with strong acids and oxidising agents during wet massing; if the formulation contains sodium metabisulfite or other reducing agents, the granulation should be processed under nitrogen because amine degradation accelerates at granule surface moisture above 2.0% w/w.

Oral Drench and Liquid Feed Supplement Solvent Thresholds

Oral delivery vehicles for ruminant anthelmintics, swine anticoccidials, and equine gastritis actives employ DMA as a co-solvent when the API is insoluble in simple glycerin or propylene glycol systems and when the final liquid must remain monophasic through freeze-thaw cycles from -5°C to 40°C. The finished drench or liquid feed concentrate typically contains DMA at 5–20% v/v, with the lower boundary dictated by API solubility and the upper boundary constrained by palatability rejection and target animal safety data generated under VICH GL43. Compliance for this dosage form references VICH GL18(R2) for residual solvent control, 21 CFR 210/211 for current good manufacturing practice if the product is marketed as a medicated feed drinking-water additive, and USP <467> for solvent identity and content by static headspace GC using a flame ionization detector. In a standard 2,000 L compounding vessel, the sequence is: charge purified water at 35–45°C, dissolve buffering salts, add DMA under moderate agitation at 300–500 rpm, then add the API through a high-shear disperser at 1,500–2,500 rpm for 15–30 min; the solution is cooled to 20–25°C, adjusted with citric acid or sodium hydroxide to pH 5.0–6.5, and filtered through a 10 µm polypropylene cartridge before filling into 1 L, 5 L, and 20 L high-density polyethylene packs. Finished product types include oral drench solutions for sheep and cattle, drinking-water concentrates for swine and poultry, and liquid feed supplements for calves. Because DMA can hydrolyse to dimethylamine at low pH and elevated temperature, long-term storage above 40°C or below pH 4.5 is to be avoided; nitrite-based antimicrobial preservatives must not be added because of NDMA formation risk, and pump calibration must be verified at the batch start because DMA changes the rheological response of the final vehicle, affecting fill volume and dose uniformity on high-speed volumetric filling lines.

When DMA is sprayed onto feed substrates as a transient carrier solvent

Medicated feed premix production introduces a different constraint: DMA must function as a short-lived solvent that deposits a uniform active layer onto sugar-starch spheres, corn cob granules, or wheat middlings, then leaves the substrate during drying to avoid carryover of a Class 2 solvent into Type B or Type C medicated feed. The solvent charge is maintained at 0.3–1.5% w/w of the premix batch; this range is selected because below 0.3% w/w the spray mass cannot adequately wet hydrophobic actives onto the carrier surface, while above 1.5% w/w the drying time in a horizontal vacuum paddle dryer becomes the throughput-limiting step. Compliance is controlled under the marketing authorization for the medicated premix and under VICH GL18(R2), with manufactured feed hygiene in the United States additionally bounded by 21 CFR Part 225 and Part 558 for new animal drugs in medicated feed; residual DMA in the finished premix is normally required to be below 200 ppm when the product is used at 10 kg/tonne of complete feed to avoid meaningful animal exposure. The production equipment typically consists of a 1,000–3,000 kg ribbon mixer with heated jacket and vacuum capability, or a conical screw dryer with a spray bar; DMA is metered through air-assisted atomising nozzles at 20–40 L/h per nozzle, with the API predissolved at 20–30% w/w solids in DMA. After spraying, the batch is dried under vacuum at 60–70°C and 15–25 kPa for 4–10 h, with residual solvent monitored by near-infrared spectroscopy calibrated against headspace GC; the endpoint is set at a DMA mass fraction below 0.02% w/w in the dried carrier. Finished products include Type B medicated feed premixes, Type C top-dress products, and granular in-feed additives for swine and poultry. The main processing conflict is dust: fine carrier fractions below 100 µm carry DMA into the dust extraction system, creating a sticky residue on filter bags and requiring a baghouse cleaning interval no longer than 24 h; product changeover must include a hot water and detergent wash of the spray bar and dryer because DMA hydrolyses slowly and can retain amine odours in stainless steel surfaces.

Lyophilized and sterile-powder veterinary lines use DMA as a prelyophilization solvent only when the API requires complete dissolution for sterile filtration but is not sufficiently soluble in tert-butanol or alcohol-water systems. In this application, DMA is charged at 8–18% v/v of the bulk filtered solution; the principal difficulty is that DMA boils at 165°C and does not sublimate under normal freeze-drying conditions, so its removal after primary drying is governed by desorption from the amorphous or crystalline matrix rather than by simple sublimation from the frozen plug. Compliance for sterile powder requires EU GMP Annex 1 for aseptic processing, USP <467> for residual solvent testing, VICH GL18(R2) for the 10.9 mg/day PDE, and container closure integrity testing according to USP <381> or equivalent. The manufacturing sequence begins with dissolution of the active in DMA at 20–30°C, addition of water and bulking agents such as mannitol, glycine, or sucrose, filtration through 0.22 µm PVDF sterilizing filters, and filling into 10 mL or 20 mL tubular glass vials. The freeze-drying cycle is the critical control point: shelf temperature is ramped from -40°C to -20°C for annealing, primary drying is conducted at -25°C to -10°C with chamber pressure 10–30 Pa, and secondary drying is extended at 25–35°C for 10–20 h under 5–15 Pa. Published data for this specific sterile-powder configuration is limited, and each formulation therefore requires design-of-experiments verification of cycle parameters because exceeding 35°C in secondary drying may collapse the cake or increase the reconstitution time beyond 2 min. Finished product types include sterile powders and lyophilized plugs for reconstitution in companion animal and livestock parenteral products. DMA is incompatible with acidic lyophilization matrices because low pH accelerates hydrolysis to dimethylamine; it should not be used with nitrite-containing excipients; and vial stoppers must be selected from fluoropolymer-coated elastomer to reduce solvent uptake during the fill interval.

Water-Soluble Powder and Granule Intermediates for Drinking-Water Medication

For drinking-water medication of poultry and swine, DMA serves as a transient granulation solvent for actives that must dissolve rapidly upon reconstitution in hard water, with batch addition held at 3–6% w/w of the dry powder blend. The solvent is pre-blended with a low-viscosity binder such as povidone K30 or hydroxypropyl methylcellulose and sprayed onto soluble carriers, typically anhydrous lactose, mannitol, or ammonium sulfate, in a vertical high-shear granulator with jacket temperature 30–40°C and impeller speed 400–600 rpm. After wet massing, the granulate is transferred to a conical vacuum dryer at 50–60°C and 10–20 kPa to reduce residual DMA below 0.05% w/w before dry milling through a 0.5 mm screen. The dried granulate is blended with effervescent salts only if fully compatible with the residual solvent profile, then filled into heat-sealed aluminium foil pouches at 100 g, 500 g, and 1 kg formats. Compliance follows VICH GL18(R2) for residual solvent control, USP <467> for headspace GC determination, and 21 CFR 210/211 for finished pharmaceutical manufacturing when the product is not registered as a medicated feed article. Terminal product types include water-soluble powders and granules for flock or herd administration via drinking-water proportioners, metering pumps, and pre-dissolved stock solutions. The process boundary is set by reconstitution pH: DMA residues above 0.08% w/w can shift a 1% w/v solution pH by 0.3–0.5 units in soft water and generate amine odour after prolonged storage in galvanised steel drinkers; therefore dryers with cold spots must be requalified after every maintenance cycle using a composite sampling plan of 12 locations across the bed.